



## **Treatment-Naive Genotype 3 Without Cirrhosis**

Recommended and alternative regimens listed by pangenotypic, evidence level and alphabetically for:

## **Treatment-Naive Genotype 3 Patients Without Cirrhosis**

RECOMMENDED	DURATION	RATING 1
Daily fixed-dose combination of glecaprevir (300 mg)/pibrentasvir (120 mg) <sup>a</sup>	8 weeks	I, A
Daily fixed-dose combination of sofosbuvir (400 mg)/velpatasvir (100 mg)	12 weeks	I, A

<sup>&</sup>lt;sup>a</sup> Dosing is 3 coformulated tablets (glecaprevir [100 mg]/pibrentasvir [40 mg]) taken once daily. Please refer to the prescribing information.

Last update: October 24, 2022